LENVIMA® (lenvatinib) 4mg
| Product Overview | |
| Generic Name | LENVIMA® (lenvatinib) 4mg |
| Brand Name(s) | Lenvima®, Lenvixi® |
| Product Type | Originator Brand |
| Form | 30 Oral capsules |
| Strength | 4mg |
| Therapeutic Class | Multikinase / receptor tyrosine kinase inhibitor; antiangiogenic activity. |
| ATC Code | L01EX08 |
| Manufacturing & Regulatory | |
| Manufacturer | Eisai |
| Country | Japan |
| GMP Compliance | FDA/EMA/WHO-GMP |
| COFEPRIS | 010.000.6171.00 |
| Free Sale Certificate | may obtain export certificate from regulatory authority |
| Logistics & Export | |
| Shelf Life | 24 Months |
| Storage | Store at 20–25 °C |
| Incoterms | EXW, HSN 300490 |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Batch CoA required from supplier/MAH. |
| CTD Summary | CTD proprietary; available under commercial agreement/license |
Description
Lenvatinib is an oral targeted oncology therapy used for radioactive iodine-refractory differentiated thyroid cancer, advanced renal cell carcinoma in combination regimens, unresectable hepatocellular carcinoma, and advanced/recurrent endometrial carcinoma in combination with pembrolizumab where indicated. It inhibits multiple receptor tyrosine kinases involved in tumour angiogenesis and tumour growth.
